Ulrike Blume-Peytavi, MD, PhD – Stough Lecturer
Vice Director Department of Dermatology, Venerology and Allergology, Director Clinical Research Center for Hair and Skin Science, Charité-Universitaetsmedizin, Berlin, Germany
Prof. Blume-Peytavi will speak on: Update on Topical Finasteride in Androgenetic Alopecia
Prof. Ulrike Blume-Peytavi is a full University professor of Dermatology and Allergology. She is Vice director of the Department of Dermatology, Venerology and Allergology, Charité – Universitätsmedizin Berlin, Director of the Clinical Research Center for Hair and Skin Science (CRC) and head of the Pediatric Dermatology unit.
Prof. Blume-Peytavi`s clinical research interests and clinical activities comprise hair disorders, pediatric dermatology and innovative topical dermatotherapy. She is author of more than 370 scientific publications, editor of the Textbook on Hair Growth and Disorders and also the editor of the German Atlas of Pediatric Dermatology.
Prof. Blume-Peytavi is an active member of different national and international societies, founding member and past president of the European Hair Research Society, the Women’s Dermatologic Society, past president of the German association of pediatric dermatology and past president and board member of the Berlin Association of Dermatology.
*****************************
Watch Lecture Intro Video
Summary Notes of Intro Video
Discussion on Prof. Ulrike Blume-Peytavi lecture at the ISHRS World Congress titled “Update on Topical Finasteride in Androgenetic Alopecia.”
Introduction:
Dr. Lam is joined by Prof. Ulrike Blume-Peytavi, renowned dermatologist and allergologist from Charité University in Berlin. Prof. Blume-Peytavi shares her groundbreaking research on topical finasteride, a promising alternative to oral finasteride. This discussion dives deep into the science, efficacy, and future possibilities of topical finasteride.
Key Discussion Points:
[00:00:12] Introduction to the Berlin ISHRS Meeting 2025:
Dr. Lam introduces the event and highlights Prof. Blume-Peytavi’s featured lecture on topical finasteride.
[00:01:00] The Development of Topical Finasteride:
Prof. Blume-Peytavi explains the motivation behind developing topical finasteride as an alternative to oral finasteride, addressing concerns about potential systemic side effects.
[00:02:10] Findings from Phase III Clinical Studies:
Efficacy: Topical finasteride demonstrated comparable results to oral finasteride in improving hair density and width.
Side Effects: Serum DHT reduction was significantly lower with topical finasteride, resulting in fewer or no systemic side effects.
[00:03:15] Dose-Finding Studies:
Prof. Blume-Peytavi discusses the process of determining the optimal dosage to balance efficacy and minimize serum DHT reduction.
[00:04:30] Formulation Insights:
The topical finasteride formulation is similar to topical minoxidil, without penetration enhancers.
The key factor for efficacy is the amount of drug in the formulation, not additional ingredients.
[00:05:20] Optimal Dosage and Application:
The licensed dosage is 2.25 mg per spray.
Up to four sprays can be applied daily to targeted regions such as the forehead and vertex.
The aerosol ensures precise delivery to the target area without dispersing to unintended regions.
[00:06:30] Future Research on Topical Dutasteride:
Dr. Lam and Prof. Blume-Peytavi discuss the potential of topical dutasteride, considering its longer half-life and systemic implications.
[00:08:00] Practical Takeaways from the ISHRS Meeting:
Dr. Lam emphasizes the practical value of the meeting, promising attendees actionable insights and pearls of wisdom to take home.
Notable Quotes:
Prof. Ulrike Blume-Peytavi:
“Topical finasteride was developed to address the concerns surrounding oral finasteride’s side effects while maintaining its efficacy.”
“The balance of effect and dosage is key—higher amounts can lead to greater DHT reduction, but the goal is to minimize systemic impact.”
Dr. Sam Lam:
“This meeting isn’t about walking away with one or two pearls; my goal is for attendees to leave with a hundred to a thousand actionable insights.”
Conclusion:
The conversation highlights the innovative approach to hair restoration with topical finasteride, offering hope for those concerned about systemic side effects. Prof. Blume-Peytavi’s research underscores the importance of targeted treatments and opens the door for future advancements in the field, including potential work on topical dutasteride.
Don’t miss the ISHRS Berlin Meeting from 23rd-25th October 2025 and get more insights on topical finasteride with Prof. Blume-Peytavi! This congress promises to be a treasure trove of practical knowledge for professionals in hair restoration surgery.